320 related articles for article (PubMed ID: 24092896)
21. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.
Kiriyama T; Kataoka H; Taoka T; Tonomura Y; Terashima M; Morikawa M; Tanizawa E; Kawahara M; Furiya Y; Sugie K; Kichikawa K; Ueno S
J Neuroimaging; 2011 Apr; 21(2):e69-77. PubMed ID: 20572907
[TBL] [Abstract][Full Text] [Related]
22. Tumefactive demyelination: an approach to diagnosis and management.
Hardy TA; Chataway J
J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1047-53. PubMed ID: 23334629
[TBL] [Abstract][Full Text] [Related]
23. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
24. Tumefactive demyelinating lesion: experience with two unusual patients.
Sinha MK; Garg RK; Bhatt ML; Chandra A
J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
[TBL] [Abstract][Full Text] [Related]
25. Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques.
Barbosa BC; Marchiori E; Leal Leidersnaider C; Brandao L; Castillo M
Neuroradiol J; 2019 Apr; 32(2):103-107. PubMed ID: 30667319
[TBL] [Abstract][Full Text] [Related]
26. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Banwell B; Bar-Or A; Arnold DL; Sadovnick D; Narayanan S; McGowan M; O'Mahony J; Magalhaes S; Hanwell H; Vieth R; Tellier R; Vincent T; Disanto G; Ebers G; Wambera K; Connolly MB; Yager J; Mah JK; Booth F; Sebire G; Callen D; Meaney B; Dilenge ME; Lortie A; Pohl D; Doja A; Venketaswaran S; Levin S; Macdonald EA; Meek D; Wood E; Lowry N; Buckley D; Yim C; Awuku M; Cooper P; Grand'maison F; Baird JB; Bhan V; Marrie RA
Lancet Neurol; 2011 May; 10(5):436-45. PubMed ID: 21459044
[TBL] [Abstract][Full Text] [Related]
27. Contralateral recurrence of tumefactive demyelination.
Khan MN; Guranda M; Essig M
Neuroradiol J; 2015 Oct; 28(5):493-7. PubMed ID: 26427896
[TBL] [Abstract][Full Text] [Related]
28. Tumefactive Demyelinating Lesion Differentiated from a Brain Tumor Using a Combination of Magnetic Resonance Imaging and (11)C-methionine Positron Emission Tomography.
Ninomiya S; Hara M; Morita A; Teramoto H; Momose M; Takahashi T; Kamei S
Intern Med; 2015; 54(11):1411-4. PubMed ID: 26027998
[TBL] [Abstract][Full Text] [Related]
29. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
[TBL] [Abstract][Full Text] [Related]
30. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
31. Demyelination preceding a diagnosis of central nervous system lymphoma.
Kalus S; Di Muzio B; Gaillard F
J Clin Neurosci; 2016 Feb; 24():146-8. PubMed ID: 26455545
[TBL] [Abstract][Full Text] [Related]
32. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion.
Law M; Meltzer DE; Cha S
Neuroradiology; 2002 Dec; 44(12):986-9. PubMed ID: 12483443
[TBL] [Abstract][Full Text] [Related]
33. Relapsing Tumefactive Demyelination: A Case Report.
Omerhodžić I; Džurlić A; Lisica D; Mahmutbegović N; Nikšić M; Bilalović N; Suljić E
Acta Med Acad; 2018 Nov; 47(2):193-198. PubMed ID: 30585071
[TBL] [Abstract][Full Text] [Related]
34. Perfusion Imaging of Tumefactive Demyelinating Lesions Compared to High Grade Gliomas.
Parks NE; Bhan V; Shankar JJ
Can J Neurol Sci; 2016 Mar; 43(2):316-8. PubMed ID: 26573406
[No Abstract] [Full Text] [Related]
35. Monofocal acute inflammatory Demyelination (MAID): a unique disorder simulating brain neoplasm.
Gutrecht JA; Berger JR; Jones RH; Mancall AC
South Med J; 2002 Oct; 95(10):1180-6. PubMed ID: 12425506
[TBL] [Abstract][Full Text] [Related]
36. Paraneoplastic tumefactive demyelination in a 47-year-old man with underlying seminoma.
Van Haver AS; Debruyne F; Sanders K; Verstappen A
Mult Scler Relat Disord; 2020 Jul; 42():102060. PubMed ID: 32217464
[TBL] [Abstract][Full Text] [Related]
37. Proton magnetic resonance spectroscopy and diffusion-weighted imaging of tumefactive demyelinating plaque.
Masu K; Beppu T; Fujiwara S; Kizawa H; Kashimura H; Kurose A; Ogasawara K; Sasaki M
Neurol Med Chir (Tokyo); 2009 Sep; 49(9):430-3. PubMed ID: 19779292
[TBL] [Abstract][Full Text] [Related]
38. Tumefactive demyelinating lesion. Trying to find unity in diversity. Comparison of two cases.
Adamek D; Radwanska E; Rog T; Grzywna E; Herman-Sucharska I
Clin Neurol Neurosurg; 2014 Jan; 116():90-2. PubMed ID: 24269051
[No Abstract] [Full Text] [Related]
39. Tumefactive demyelinating lesions: a clinicopathological correlative study.
Neelima R; Krishnakumar K; Nair MD; Kesavadas C; Hingwala DR; Radhakrishnan VV; Nair SS
Indian J Pathol Microbiol; 2012; 55(4):496-500. PubMed ID: 23455787
[TBL] [Abstract][Full Text] [Related]
40. Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease-Preliminary Experience From a Retrospective Analysis.
Barbagallo M; Albatly AA; Schreiner S; Hayward-Könnecke HK; Buck A; Kollias SS; Huellner MW
Clin Nucl Med; 2018 Nov; 43(11):e385-e391. PubMed ID: 30153143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
